Cargando…

Under Development JAK Inhibitors for Dermatologic Diseases

Molecular targeting therapies represent a new exciting era in dermatology. A promising novel drug class, subject of intense research, is Janus kinase (JAK) inhibitors. Multiple cytokine receptors signal through the Janus kinase and signal transducer and activator of transcription (STAT) pathway. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sideris, Nikolaos, Vakirlis, Efstratios, Tsentemeidou, Aikaterini, Kourouklidou, Alexandra, Ioannides, Demetrios, Sotiriou, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361191/ https://www.ncbi.nlm.nih.gov/pubmed/32676572 http://dx.doi.org/10.31138/mjr.31.1.137

Ejemplares similares

Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis
por: Tsentemeidou, Aikaterini, et al.
Publicado: (2022)

Apremilast Survival and Reasons for Discontinuation in Psoriasis: Five-Year Experience From a Greek Tertiary Care Centre
por: Sotiriou, Elena, et al.
Publicado: (2022)

Apremilast in Psoriasis Patients With Serious Comorbidities: a Case Series and Systematic Review of Literature
por: Tsentemeidou, Aikaterini, et al.
Publicado: (2022)

New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature
por: Sideris, Nikolaos, et al.
Publicado: (2022)

A retrospective epidemiological study of skin diseases among pediatric population attending a tertiary dermatology referral center in Northern Greece
por: Vakirlis, Efstratios, et al.
Publicado: (2017)

Sebaceous Neoplasms
por: Papadimitriou, Ilias, et al.
Publicado: (2023)

Re-Evaluating Limitations in Atopic Dermatitis Meta-Analysis Is Important in Interpreting its Results: Limitations of Atopic Dermatitis meta-analysis
por: Vakirlis, Efstratios, et al.
Publicado: (2021)

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008)

Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy
por: Apalla, Zoe, et al.
Publicado: (2017)

Atypical case of lichen planus recognized by dermoscopy
por: Papageorgiou, Chrysoula, et al.
Publicado: (2016)

Rosacea and Helicobacter pylori: links and risks
por: Lazaridou, Elizabeth, et al.
Publicado: (2017)

Scabies escaping detection until dermoscopy was applied
por: Lallas, Aimilios, et al.
Publicado: (2017)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
por: Fotiadou, Christina, et al.
Publicado: (2016)

Clinicopathologically problematic melanocytic tumors: a case-based review
por: Apalla, Zoe, et al.
Publicado: (2018)

JAK-STAT pathway inhibitors in dermatology()
por: Miot, Hélio Amante, et al.
Publicado: (2023)

Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?
por: Bakirtzi, Katerina, et al.
Publicado: (2023)

Delayed skin cancer diagnosis in 2020 because of the COVID-19–related restrictions: Data from an institutional registry
por: Lallas, Aimilios, et al.
Publicado: (2021)

Emerging Topical and Systemic JAK Inhibitors in Dermatology
por: Solimani, Farzan, et al.
Publicado: (2019)

Atopic Dermatitis and Water: Is There an Optimum Water Intake Level for Improving Atopic Skin?
por: Douladiris, Nikolaos, et al.
Publicado: (2023)

A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
por: Samuel, Christeen, et al.
Publicado: (2023)

Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou, Christina, et al.
Publicado: (2018)

Epidemiological trends in skin cancer
por: Apalla, Zoe, et al.
Publicado: (2017)

Clinical efficacy of new JAK inhibitors under development. Just more of the same?
por: Westhovens, Rene
Publicado: (2019)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology
por: Jessica Chang, Ting Yi, et al.
Publicado: (2020)

Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
por: Lallas, Aimilios, et al.
Publicado: (2016)

The Role of Tight Junctions in Atopic Dermatitis: A Systematic Review
por: Katsarou, Spyridoula, et al.
Publicado: (2023)

Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
por: Richter, Patricia, et al.
Publicado: (2022)

JAK inhibitors and COVID-19
por: Levy, Gabriel, et al.
Publicado: (2022)

Patch Testing in Patients With Alopecia Areata: A Case-series Study
por: Kyrmanidou, Eirini, et al.
Publicado: (2022)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Melanoma: Staging and Follow-Up
por: Papageorgiou, Chryssoula, et al.
Publicado: (2021)

Efficacy of JAK inhibitors in Crohn’s Disease
por: Rogler, Gerhard
Publicado: (2020)

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
por: Bertsias, George
Publicado: (2020)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Dermatological Manifestations in Pediatric Inflammatory Bowel Disease
por: Diaconescu, Smaranda, et al.
Publicado: (2020)

Psoriasis and Psycho-Dermatology
por: Moon, Hee-Sun, et al.
Publicado: (2013)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rime400sm65biln7r0c105nl23